New drug UP-818-CC passes first safety check in healthy volunteers

NCT ID NCT07355621

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested the safety and tolerability of a new drug, UP-818-CC, in 73 healthy Chinese volunteers. Participants received either a single dose or multiple daily doses of the drug or a placebo. The main goal was to check for side effects and measure how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

UP-818-CC injection

What this could lead to

If successful, this could pave the way for future studies testing UP-818-CC as a potential treatment for an unspecified condition.

What could go wrong

This is an early Phase 1 safety study in healthy people, so it cannot show whether the drug works for any disease. Side effects may emerge.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Huashan Hospital Fudan University

    Shanghai, China